CoreBiome Awarded Technology Commercialization Grant

ST. PAUL, Minn.--()--CoreBiome, a microbiome analysis and discovery company, was awarded a $220,000 grant to accelerate the commercialization of technology licensed from the University of Minnesota.

“This grant will allow CoreBiome to accelerate its R&D pipeline and bring new products based on the licensed technology to market faster,” said Daryl Gohl, CoreBiome’s Chief Scientific Officer.

The grant funding comes from the Translational Product Development Fund (TPDF) Biomedicine and Bioethics Innovation Grant program, which is funded by the State of Minnesota and co-administered by the University of Minnesota, Clinical and Translational Science Institute and the Mayo Clinic Center for Clinical and Translational Science. The TPDF program aims to impact the lives of Minnesotans by translating research discoveries into new therapies and treatment approaches for patients.

“The microbiome plays an extremely important role in human health and disease and we are thrilled to support CoreBiome’s technologies and their potential to accelerate the drug discovery process and impact the lives of patients,” said Tucker LeBien, Associate Vice President for Research of the University of Minnesota’s Academic Health Center.

CoreBiome has licensed technology from the University of Minnesota for synthetic DNA standards, which are used as controls for quality assurance in the microbiome sequencing process. In addition, the company licensed novel algorithms developed in the lab of co-founder and CEO, Dan Knights. In June, CoreBiome announced the launch of its BoosterShot™ platform, the first microbiome shotgun sequencing test priced under $100. BoosterShot™ is enabled by CoreBiome’s advances in informatics and genomics and allows for high-resolution profiling of the microbiome in the context of large-scale studies.

About CoreBiome:
CoreBiome is a microbiome genomics company focused on accelerating discovery for customers in the pharmaceutical, agriculture, and research communities, to unleash the translational potential of the microbiome. The company’s proprietary BenchMark™, BoosterShot™, StrainView™, and Core Analysis™ platforms provide fast and information-rich characterizations of microbial diversity and function, paired with machine learning and expert analytics. For more information about CoreBiome, visit http://www.corebiome.com.

Contacts

CoreBiome
Eve Grabau
egrabau@corebiome.com

Release Summary

CoreBiome, a microbiome analysis and discovery company, was awarded a $220,000 grant for the commercialization of technology licensed from UMN.

Contacts

CoreBiome
Eve Grabau
egrabau@corebiome.com